GHRS:NASDAQ, GH Research PLC
GHRS stock overview
GH Research PLC (GHRS:NASDAQ) closed at $17.53 on November 20, 2026,
down 5.55% on the day.
The stock trades 44.2% below its 52-week high of $31.44
and 45.6% above its 52-week low of $12.04.
Over the past year, it gained 20.2%.
GH Research PLC is part of the Health Care sector.
Key figures
- Price
- $17.53
- Day change
- -5.55%
- Volume
- 298,833
- Average volume
- 292,237
- Market cap
- 1B+
- 52-week range
- $12.04 – $31.44
- 50-day average
- $21.56
- 200-day average
- $21.75
Price action over the past year
In 252 trading sessions since November 20, 2025, GHRS closed higher on 126 days (50%).
Its best day was January 7, 2026 (+27.12%) and its worst was January 8, 2026 (-13.37%).
The stock moved 10% or more in a single session 7 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
GHRS news
-
Nov 21, 2026:
Chief Development Hire And Earnings Update Put GH Research Stock In Focus
-
Nov 20, 2026:
Wall Street Analysts See a 128.66% Upside in GH Research (GHRS): Can the Stock Really Move This High?
-
Nov 16, 2026:
Is GH Research (GHRS) Overvalued Even After Positive FDA Feedback?
-
Nov 13, 2026:
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
-
Nov 13, 2026:
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
-
Nov 1, 2026:
GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger
-
Oct 18, 2026:
GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price
-
Aug 25, 2026:
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Similar stocks
Find more stocks like GHRS with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.